In the current study, we found that DNMT1-mediated FOXO3a promoter hypermethylation leads to downregulation of FOXO3a expression in breast cancer, and FOXO3a suppresses BCSC properties and tumorigenicity via inhibition of FOXM1/SOX2 signaling. The gene discussed is FOXM1; the disease is breast cancer.